Biopharmaceutical company GSK plc (LSE/NYSE:GSK) on Friday announced positive results from a phase III trial evaluating the combination of Zejula (niraparib) and Jemperli (dostarlimab) in first-line advanced ovarian cancer.

The primary endpoint of progression-free survival (PFS) was met, demonstrating a statistically significant improvement with the addition of dostarlimab to standard-of-care treatments.

While the secondary endpoint of overall survival did not reach statistical significance, further analyses are ongoing. The safety and tolerability profile of the combination was generally consistent with that of the individual agents.